The ADAM10 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 143B osteosarcoma cell line. This product provides a loss-of-function model for studying the ADAM10 sheddase in bone cancer and related signaling pathways. The polyclonal knockout approach results in a pool of cells carrying diverse gene disruptions at the ADAM10 locus, offering a robust system to investigate ADAM10-dependent biological processes without clonal selection biases.
The 143B cell line is a widely used human osteosarcoma model derived from a primary osteosarcoma, known for its high metastatic potential and utility in bone cancer research. These cells are particularly valuable for studying tumor progression, invasion, and metastasis. They exhibit aggressive in vivo growth and are commonly employed to examine the mechanisms underlying osteosarcoma biology and to test potential therapeutic interventions.
ADAM10 is a disintegrin and metalloprotease that functions as a key ectodomain sheddase, releasing the extracellular domains of numerous transmembrane proteins. It is activated by TSPAN15 and TSPAN33, and its activity is inhibited by TIMP-1 and TIMP-3. ADAM10 cleaves Notch receptors, initiating a cascade where the Notch intracellular domain (NICD) is further processed by ??-secretase to activate CSL-dependent transcription of target genes such as HES1. Additionally, ADAM10 sheds E-cadherin, CD44, and HB-EGF, thereby modulating cell adhesion and EGFR signaling. It also processes sAPP?? and soluble IL-6R, influencing a broad range of cellular functions.
In 143B osteosarcoma cells, ADAM10 knockout is expected to perturb multiple malignancy-associated pathways. Loss of ADAM10 impairs Notch signaling, which can reduce the expression of oncogenic target genes and potentially decrease cell proliferation and survival. Simultaneously, disruption of E-cadherin shedding may alter cell?Ccell adhesion complexes, influencing the invasive and metastatic behavior characteristic of these aggressive tumor cells. This model therefore offers a powerful tool to dissect the contributions of ADAM10 to osteosarcoma progression, including processes such as migration, invasion, and chemoresistance.
Researchers can employ these ADAM10 knockout 143B polyclonal cells in a variety of functional and mechanistic studies. Typical applications include assessing ADAM10-dependent sheddase activity via ELISA for soluble E-cadherin or sAPP??, examining Notch pathway activation through NICD western blotting or HES1 RT-qPCR, and monitoring cell migration and invasion using wound healing and Transwell assays. The polyclonal nature ensures a comprehensive loss-of-function effect while avoiding individual clone artifacts, making the cells suitable for drug screening, pathway dissection, and identification of novel ADAM10 substrates. For further information or technical support, please contact Ascent Research.
